ALOXI® vs. Ondansetron and Dolasetron: Pooled Data
ALOXI® DELIVERS POWER OVER CINV
BETTER IN ACUTE, BETTER IN DELAYED, BETTER OVERALL
- A single IV dose of ALOXI 30 minutes prior to chemotherapy offers prolonged prevention of CINV for up to 5 days.1-4
- ALOXI is the first and only 5-HT3 antagonist indicated for the prevention of acute and delayed CINV following moderately emetogenic chemotherapy.5-8
- Significantly more patients receiving ALOXI achieved a complete response compared with those who were receiving ondansetron/dolasetron during acute, delayed and overall periods.1-4
- Significantly more patients receiving ALOXI were free from nausea than those receiving ondansetron/dolasetron on days 2-5 following moderately emetogenic chemotherapy.1-4
Click here to view the results of the ALOXI vs. Ondansetron and Dolasetron in Patients with Breast Cancer.
References
- Rubenstein EB, Gralla RJ, Eisenberg P, et al. Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV): combined results of two phase III trials. Proc Am Soc Clin Oncol. 2003;22:729. Abstract 2932.
- Rubenstein EB, Macciocchi A. The efficacy of a single fixed 0.25-mg intravenous (IV) dose of palonosetron (PALO) in preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV) is not affected by body weight. Support Care Cancer 2004; 12:373-374. Abstract A-26. Poster presented at the Multinational Association of Supportive Care in Cancer (MASCC) 16h International Symposium on Supportive Care in Cancer; June 24-27, 2004; Miami, FL, USA.
- Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98:2473-2482.
- Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570-1577.
- ALOXI® (palonosetron HCl) injection full prescribing information.
- Anzemet® (dolasetron mesylate) full prescribing information.
- Zofran® (ondansetron hydrochloride) full prescribing information.
- Kytril® (granisetron hydrochloride) full prescribing information.
During initial and repeat courses of chemotherapy, ALOXI helps prevent and control nausea and vomiting the day following chemotherapy that is highly likely to cause nausea and vomiting, and for up to 5 days following chemotherapy that is likely to cause nausea and vomiting.
The most frequent side effects of ALOXI include headache and constipation. If you have or may develop significant heart rhythm changes, talk with your healthcare professional before receiving ALOXI.
ALOXI is available by prescription only. Please see the important product information for ALOXI for more information.
This site does not contain everything that is known about ALOXI. If you would like to know more, talk to your healthcare professional.